Embryonic Signaling Pathways and Rhabdomyosarcoma: Contributions to Cancer Development and Opportunities for Therapeutic Targeting

Table 2

Clinical trials evaluating drugs that target Notch, WNT, or Hedgehog signaling pathways in children.

ClinicalTrials.gov no.	Indication	Compound	Mechanism	Phase	Start date	Completion date	Sponsor/collaborator
Notch
NCT00100152	Relapsed/refractory T cell ALL/lymphoma	MK0752	Gamma-secretase inhibitor	I	Jul 2005	Oct 2006	Merck
NCT01088763	Relapsed/refractory solid tumors, CNS tumors, lymphoma, T cell leukemia	RO4929097	Gamma-secretase inhibitor	I/II	Mar 2010	May 2011	Children’s Oncology Group/NCI
NCT01236586	Relapsed/refractory solid tumors, CNS tumors, lymphoma, T cell leukemia	RO4929097	Gamma-secretase inhibitor	I/II	Oct 2010	Apr 2011	NCI/NIH CC
WNT
Hedgehog
NCT00822458	Recurrent/refractory medulloblastoma	GDC-0049	Smo small-molecule inhibitor	I	Jan 2009	Jul 2011	Pediatric brain tumor consortium/NCI
NCT01239316	Recurrent/refractory medulloblastoma	GDC-0449	Smo small-molecule inhibitor	II	Nov 2010	Ongoing	Pediatric brain tumor consortium/NCI
NCT01125800	Medulloblastoma, rhabdomyosarcoma, neuroblastoma, hepatoblastoma, high-grade glioma, astrocytoma	LDE225	Smo small-molecule inhibitor	I	Feb 2011	Ongoing	Novartis Pharmaceuticals

Obtained from clinicaltrials.gov website January 8, 2012.